FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175216304> ?p ?o ?g. }

• W3175216304 abstract "Background: Liver fibrosis is a consequence of chronic inflammation and is associated with protein changes within the hepatocytes structure. We therefore investigated urinary peptides in patients with liver fibrosis.Methods: Multicentre case-control prospective study. 129 patients with varying degrees of liver fibrosis and 223 controls without liver fibrosis were recruited. Additionally, 41 patients with no liver, but kidney fibrosis were included to evaluate interference with expressions of kidney fibrosis. Urinary low molecular weight proteome was then analysed by capillary electrophoresis coupled to mass spectrometry (CE-MS).Findings: CE-MS enabled identification of 50 urinary peptides associated with liver fibrosis. When combined into a classifier, LivFib-50, it separated liver fibrosis from controls with an area under the curve (AUC) of 0.95 (95% confidence intervals (CI): 0.90-0.98, p<0.0001) with 83.5% sensitivity and 95.1% specificity. In the first validation cohort, LivFib-50 demonstrated an AUC of 0.94 (95% CI: 0.89-0.97, p<0.0001). In a second validation cohort, LivFib-50 was adjusted for age and demonstrated an AUC of 0.91 (95% CI: 0.76 -0.98, p<0.0001). Age-adjusted LivFib-50 showed 84.2% sensitivity (95% CI: 60.4 - 96.6) and 82.4% specificity (95% CI: 56.6 - 96.2) for detection of liver fibrosis. The sequence-identified peptides were mainly fragments of collagen chains, uromodulin and Na/K-transporting ATPase subunit γ. We also identified ten putative proteolytic cleavage sites, eight were specific for matrix metallopeptidases and two for cathepsins.Interpretation: In liver fibrosis, urinary peptides profiling offers potential diagnostic markers and leads to discovery of proteolytic sites that could be targets for developing anti-fibrotic therapy.Funding Statement: This manuscript was supported by research grant from the medical and life sciences research fund (MLSRF) which was awarded to AB. It is charity that supports research and education to enhance human health and had no role in study design or methodology.Declaration of Interests: Harald Mischak is founder and co-owner of Mosaiques Diagnostics GmbH, which developed the CE-MS technology. Jochen Metzger and Martin Pejchinovski are employees of Mosaiques Diagnostics GmbH. All other authors declare no conflict of interest.Ethics Approval Statement: The study was approved by the relevant Ethics and R&D Committees (Ref 18717 and Ref 260179). Study was conducted according to the World Medical Association Declaration of Helsinki, with all study participants providing written informed consent." @default.
• W3175216304 created "2021-07-05" @default.
• W3175216304 creator A5002183557 @default.
• W3175216304 creator A5004011707 @default.
• W3175216304 creator A5009836615 @default.
• W3175216304 creator A5031670965 @default.
• W3175216304 creator A5037762556 @default.
• W3175216304 creator A5049251749 @default.
• W3175216304 creator A5050242553 @default.
• W3175216304 creator A5052560289 @default.
• W3175216304 creator A5057962416 @default.
• W3175216304 creator A5058039778 @default.
• W3175216304 creator A5091055995 @default.
• W3175216304 date "2020-01-01" @default.
• W3175216304 modified "2023-09-23" @default.
• W3175216304 title "Discovery, Validation and Sequencing of Urinary Peptides for Diagnosis of Liver Fibrosis —A Multicentre Study" @default.
• W3175216304 doi "https://doi.org/10.2139/ssrn.3679865" @default.
• W3175216304 hasPublicationYear "2020" @default.
• W3175216304 type Work @default.
• W3175216304 sameAs 3175216304 @default.
• W3175216304 citedByCount "0" @default.
• W3175216304 crossrefType "journal-article" @default.
• W3175216304 hasAuthorship W3175216304A5002183557 @default.
• W3175216304 hasAuthorship W3175216304A5004011707 @default.
• W3175216304 hasAuthorship W3175216304A5009836615 @default.
• W3175216304 hasAuthorship W3175216304A5031670965 @default.
• W3175216304 hasAuthorship W3175216304A5037762556 @default.
• W3175216304 hasAuthorship W3175216304A5049251749 @default.
• W3175216304 hasAuthorship W3175216304A5050242553 @default.
• W3175216304 hasAuthorship W3175216304A5052560289 @default.
• W3175216304 hasAuthorship W3175216304A5057962416 @default.
• W3175216304 hasAuthorship W3175216304A5058039778 @default.
• W3175216304 hasAuthorship W3175216304A5091055995 @default.
• W3175216304 hasBestOaLocation W31752163042 @default.
• W3175216304 hasConcept C126322002 @default.
• W3175216304 hasConcept C2777214474 @default.
• W3175216304 hasConcept C2994217296 @default.
• W3175216304 hasConcept C71924100 @default.
• W3175216304 hasConcept C77411442 @default.
• W3175216304 hasConceptScore W3175216304C126322002 @default.
• W3175216304 hasConceptScore W3175216304C2777214474 @default.
• W3175216304 hasConceptScore W3175216304C2994217296 @default.
• W3175216304 hasConceptScore W3175216304C71924100 @default.
• W3175216304 hasConceptScore W3175216304C77411442 @default.
• W3175216304 hasLocation W31752163041 @default.
• W3175216304 hasLocation W31752163042 @default.
• W3175216304 hasOpenAccess W3175216304 @default.
• W3175216304 hasPrimaryLocation W31752163041 @default.
• W3175216304 hasRelatedWork W2090183083 @default.
• W3175216304 hasRelatedWork W2119477742 @default.
• W3175216304 hasRelatedWork W2391905019 @default.
• W3175216304 hasRelatedWork W2406164672 @default.
• W3175216304 hasRelatedWork W2412574627 @default.
• W3175216304 hasRelatedWork W2517659937 @default.
• W3175216304 hasRelatedWork W3003057451 @default.
• W3175216304 hasRelatedWork W4226022271 @default.
• W3175216304 hasRelatedWork W4235671009 @default.
• W3175216304 hasRelatedWork W4288392727 @default.
• W3175216304 isParatext "false" @default.
• W3175216304 isRetracted "false" @default.
• W3175216304 magId "3175216304" @default.
• W3175216304 workType "article" @default.